Avadel, Lumryz and narcolepsy
Avadel wins FDA approval for narcolepsy drug Lumryz in children
The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz’s path to market.
US FDA expands use of Avadel's sleep disorder drug to ages 7 and up
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and older, broadening its use and heating up competition for widely used treatments from Jazz Pharma.
Avadel's narcolepsy drug Lumryz gets USFDA approval for pediatric use
Avadel's drug contains a central nervous system depressant drug called sodium oxybate, which helps increase the amount of time someone spends in deep sleep.
Avadel Obtains FDA Nod for Label Expansion of Narcolepsy Drug Lumryz
The FDA approves AVDL's Lumryz for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients aged seven years and older with narcolepsy.
Avadel Gets Expanded FDA OK of Lumryz for Use in Children
Avadel Pharmaceuticals has won expanded Food and Drug Administration approval of its narcolepsy drug Lumryz for use in children. Avadel on Thursday said the FDA nod covers Lumryz for the treatment of cataplexy, or excessive daytime sleepiness, in children ages seven and older with narcolepsy, a chronic sleep disorder.
Avadel Pharma's SNDA For Lumryz Gets FDA Approval
Biopharmaceutical company Avadel Pharmaceuticals plc (AVDL), Thursday announced that the U.S. Food and Drug Administration (FDA) has
FDA OKs Once-Nightly Lumryz for Children with Narcolepsy
Lumryz is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in children as young as 7 years with narcolepsy.
Analysts Are Bullish on These Healthcare Stocks: Avadel Pharmaceuticals (AVDL), Rani Therapeutics Holdings (RANI)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research ...
US FDA expands approval for Avadel's sleep disorder drug
The U.S. Food and Drug Administration has approved Avadel Pharmaceuticals' sleep disorder drug for children aged 7 years and ...
Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...
ENDPOINTS NEWS1d
FDA ex­pands la­bel for Avadel's nar­colep­sy drug in­to chil­dren
Avadel Pharmaceuticals said its once-nightly narcolepsy drug Lumryz can now be used to treat children older than 7 years of ...
Cetera Investment Advisers Sells 6,191 Shares of Avadel Pharmaceuticals plc (NASDAQ:AVDL)
Cetera Investment Advisers trimmed its position in Avadel Pharmaceuticals plc (NASDAQ:AVDL – Free Report) by 5.4% during the second quarter, according to the company in its most recent 13F filing with ...